Selected article for: "lopinavir ritonavir and lung inflammation"
Author: Indari, Omkar; Jakhmola, Shweta; Manivannan, Elangovan; Jha, Hem Chandra
Title: An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?
  • Cord-id: qrfrrpsg
  • Document date: 2021_3_8
    • ID: qrfrrpsg
    Snippet: COVID-19 pandemic has spread worldwide at an exponential rate affecting millions of people instantaneously. Currently, various drugs are under investigation to treat an enormously increasing number of COVID-19 patients. This dreadful situation clearly demands an efficient strategy to quickly identify drugs for the successful treatment of COVID-19. Hence, drug repurposing is an effective approach for the rapid discovery of frontline arsenals to fight against COVID-19. Successful application of th
    Document: COVID-19 pandemic has spread worldwide at an exponential rate affecting millions of people instantaneously. Currently, various drugs are under investigation to treat an enormously increasing number of COVID-19 patients. This dreadful situation clearly demands an efficient strategy to quickly identify drugs for the successful treatment of COVID-19. Hence, drug repurposing is an effective approach for the rapid discovery of frontline arsenals to fight against COVID-19. Successful application of this approach has resulted in the repurposing of some clinically approved drugs as potential anti-SARS-CoV-2 candidates. Several of these drugs are either antimalarials, antivirals, antibiotics or corticosteroids and they have been repurposed based on their potential to negate virus or reduce lung inflammation. Large numbers of clinical trials have been registered to evaluate the effectiveness and clinical safety of these drugs. Till date, a few clinical studies are complete and the results are primary. WHO also conducted an international, multi-country, open-label, randomized trials-a solidarity trial for four antiviral drugs. However, solidarity trials have few limitations like no placebos were used, additionally any drug may show effectiveness for a particular population in a region which may get neglected in solidarity trial analysis. The ongoing randomized clinical trials can provide reliable long-term follow-up results that will establish both clinical safety and clinical efficacy of these drugs with respect to different regions, populations and may aid up to worldwide COVID-19 treatment research. This review presents a comprehensive update on majorly repurposed drugs namely chloroquine, hydroxychloroquine, remdesivir, lopinavir-ritonavir, favipiravir, ribavirin, azithromycin, umifenovir, oseltamivir as well as convalescent plasma therapy used against SARS-CoV-2. The review also summarizes the data recorded on the mechanism of anti-SARS-CoV-2 activity of these repurposed drugs along with the preclinical and clinical findings, therapeutic regimens, pharmacokinetics, and drug-drug interactions.

    Search related documents:
    Co phrase search for related documents
    • active form and adenosine triphosphate: 1, 2, 3, 4, 5
    • activity effect and acute cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • activity effect and acute respiratory failure: 1
    • activity effect and adenosine triphosphate: 1, 2
    • activity effect and liver unstable: 1
    • activity effect and lopinavir ritonavir: 1, 2
    • activity effect and low frequency: 1, 2
    • acute cov respiratory syndrome coronavirus and adenosine triphosphate: 1, 2, 3, 4, 5, 6
    • acute cov respiratory syndrome coronavirus and liver transaminase: 1, 2, 3
    • acute cov respiratory syndrome coronavirus and liverpool interaction: 1
    • acute cov respiratory syndrome coronavirus and long course: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute cov respiratory syndrome coronavirus and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute cov respiratory syndrome coronavirus and low frequency: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • acute respiratory failure and liver transaminase: 1
    • acute respiratory failure and long course: 1, 2, 3
    • acute respiratory failure and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute respiratory failure and low frequency: 1, 2
    • liver transaminase and lopinavir ritonavir: 1, 2, 3
    • liverpool interaction and lopinavir ritonavir: 1, 2, 3, 4